Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation (Q35057258)

6 August 2017

1 reference

title

Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation (English)

1 reference

6 August 2017

1 reference

1 reference

Ijaz A Khan

1

1 reference

6 August 2017

publication date

1 February 2003

1 reference

International Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

87

1 reference

6 August 2017

issue

2-3

1 reference

6 August 2017

page(s)

121-128

1 reference

Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Short-term effect of atrial fibrillation on atrial contractile function in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Rhythm management in atrial fibrillation--with a primary emphasis on pharmacological therapy: Part 2

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Cardioversion with flecainide in patients with atrial fibrillation of recent onset

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Absorption kinetics of oral and rectal flecainide in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Estimation of the absolute bioavailability of flecainide using stable isotope technique

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Flecainide: a new prototype antiarrhythmic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Flecainide pharmacokinetics in healthy volunteers: the influence of urinary pH.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

Effects of flecainide on ventricular function: clinical and experimental correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900467-9

7 January 2021

10.1016/S0167-5273(02)00467-9

Identifiers

DOI

1 reference

6 August 2017

1 reference